Percutaneous Aortic Valve Implant The US Experience The Partner Trial (pp. 241-262)
Authors: (Imran N. Ahmad, E. Murat Tuzcu, and Samir R. Kapadia)
Abstract: Calcific aortic stenosis (AS) is the most common cause of aortic stenosis in adults with a prevalence of 2% in patients 65 years of age or older.[1, 2] Although patients may remain asymptomatic for many years, the onset of symptoms predicts rapid disease progression with an almost 50% mortality rate at 2 years.
The gold standard therapy is surgical aortic valve replacement (AVR), however, in excess of 30% of patients may be denied surgery due to advanced age, significant left ventricular dysfunction, previous chest surgery or radiation, or other co-morbidities.[4-6] For this group of patients, until recently with the advent of transcatheter aortic valve implantation (TAVI) there were no therapies available that could provide either a mortality benefit or lasting symptom relief.
In this chapter, we review the Edwards SAPIEN transcatheter aortic heart valve system (Edwards Lifesciences, Irvine, CA) in the context of the U.S. randomized Placement of Aortic Transcatheter Valves (PARTNER) trial including design, patient selection, role of imaging, and complications.